Shockwave Medical (NASDAQ:SWAV) announced its earnings results on Wednesday, May 8th. The company reported ($1.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.85), Fidelity Earnings reports. The company had revenue of $7.27 million during the quarter.
NASDAQ:SWAV opened at $59.79 on Friday. Shockwave Medical has a 52 week low of $24.58 and a 52 week high of $66.76.
SWAV has been the topic of a number of recent research reports. Bank of America initiated coverage on Shockwave Medical in a report on Monday, April 1st. They issued a “neutral” rating and a $37.00 target price on the stock. Morgan Stanley initiated coverage on Shockwave Medical in a report on Monday, April 1st. They issued an “equal weight” rating and a $32.00 target price on the stock. Finally, Wells Fargo & Co started coverage on Shockwave Medical in a report on Monday, April 1st. They issued a “market perform” rating and a $33.00 target price on the stock.
About Shockwave Medical
ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.